Skip to main content
. Author manuscript; available in PMC: 2009 Sep 1.
Published in final edited form as: Gynecol Oncol. 2008 Jul 1;110(3):329–335. doi: 10.1016/j.ygyno.2008.05.008

Table 5.

Toxicity in feasibility phase

Grade
Adverse Effect 0 1 2 3 4 Total
Leukopenia 1 0 7 11 1 20
Thrombocytopenia 1 2 1 16 0 20
Neutropenia 0 0 0 1 19 20
Anemia 0 3 14 3 0 20
Allergy 19 1 0 0 0 20
Cardiovascular 17 2 0 1 0 20
Constitutional 3 14 2 1 0 20
Dermatologic 8 7 4 1 0 20
Gastrointestinal 3 8 8 1 0 20
Genitourinary/Renal 19 1 0 0 0 20
Hemorrhage 18 1 0 1 0 20
Hepatic 11 8 1 0 0 20
Infection 19 0 0 1 0 20
Metabolic 11 5 2 2 0 20
Neuropathy-sensory 5 11 3 1 0 20